Axsome Therapeutics: 35% Upside or Setback Ahead?

Axsome Therapeutics (NASDAQ: AXSM) has delivered substantial returns, with its shares increasing by approximately 660% over the last five years. Wall Street maintains a positive outlook, setting an average price target of $285.42, which suggests a potential 35% increase from current levels within the next 12 months.

The company's financial performance in the second quarter showed a 46% year-over-year revenue increase to $218.4 million. A primary driver of this growth is Auvelity, a depression medication that generated $180.3 million in sales, a 51% rise from the previous year. Auvelity recently received a label expansion for Alzheimer's disease agitation, significantly broadening its addressable market.

Axsome also markets Sunosi for narcolepsy and Symbravo for migraines. The company anticipates meaningful clinical and regulatory progress in the upcoming year, including Phase 3 trials for AXS-14 (fibromyalgia) and preparations for AXS-20 (schizophrenia). Additionally, AXS-12 for narcolepsy could receive approval by May 2027.

While near-term stock movements can be unpredictable due to market challenges or regulatory hurdles, Axsome's medium-term prospects appear robust. The company possesses an attractive late-stage pipeline with potential for new product approvals or significant clinical trial results within the next three years. Even with potential setbacks, the depth of its pipeline positions Axsome to potentially achieve competitive returns through 2031.